GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

GRI Bio, Inc. Common Stock

GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant NKT (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.

National Science Foundation

GRI Bio, Inc.

Our CEO, Dr. Marc Hertz, highlights our novel approach to #immunemodulation. Watch the full video here: https://bit.ly/3FvbDJn  

#NKT #AutoimmuneDisease #InflammatoryDisease #FibroticDisease

GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis.

https://bit.ly/3GvZu7M 
#IdiopathicPulmonaryFibrosis #IPF #FibroticDisease

Access our library of scientific publications for a comprehensive review of our data. https://bit.ly/3OhuOf8  

#AutoimmuneDisease #PulmonaryDisease #FibroticDisease

#WhatThisMeans: Drs. Marc Hertz and Al Agro, CEO and CMO of GRI Bio, Inc., highlight the Company’s recent IND clearance for lead program targeting #idiopathicpulmonaryfibrosis. 

https://lnkd.in/eUEkB7DC
#IPF #NKT #FibroticDisease

GRI Bio Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant #NKT Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis.

https://bit.ly/47we2Qm 
#IdiopathicPulmonaryFibrosis #IPF #FibroticDisease

We hope your Thanksgiving table is full of your favorite food and surrounded by your favorite people.

Regulating #NKT cells is a selective approach to #immunomodulation via resetting the immune response. Learn more here: https://bit.ly/3pRUJAu  

#AutoimmuneDisease #PulmonaryDisease #FibroticDisease

GRI Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update.

https://bit.ly/47ce5kt 
#NKT #AutoimmuneDisease #PulmonaryDisease #FibroticDisease

Email alerts make it easy to stay up to date! Sign up here: https://bit.ly/45GwuVq  

#NKT #AutoimmuneDisease #PulmonaryDisease #FibroticDisease

We are dedicated to advancing new therapies through innovative approaches for the treatment of #inflammatory, #fibrotic and #autoimmune diseases. 

#NKT

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-3.46M -	-4.82M 39.18%	-1.56M 67.67%	-3.22M 106.35%	-13.04M 305.25%
depreciation and amortization	735 -	75K 10,104.08%	49K 34.67%	50K 2.04%	57K 14.00%
deferred income tax				325K -
stock based compensation				25K -
change in working capital	159.67K -	887K 455.53%	563K 36.53%	1.51M 169.09%	1.68M 10.89%
accounts receivables
inventory
accounts payables	-40.28K -	980K 2,532.73%	54K 94.49%	897K 1,561.11%	2.16M 140.69%
other working capital	199.95K -	-93K 146.51%	509K 647.31%	618K 21.41%	-479K 177.51%
other non cash items	420.35K -	154K 63.36%	100K 35.06%	217K 117%	2.16M 895.39%
net cash provided by operating activities	-2.88M -	-3.71M 28.51%	-847K 77.15%	-1.08M 28.10%	-9.14M 742.40%
investments in property plant and equipment		-2K -		-3K -	-8K 166.67%
acquisitions net
purchases of investments			-3.84M -	-640K 83.34%
sales maturities of investments				4.42M -
other investing activites				-3.78M -
net cash used for investing activites		-2K -	-3.84M 192,000%	-3K 99.92%	-8K 166.67%
debt repayment	-1.11M -	-4K 99.64%	-244K 6,000%	-250K 2.46%	-1.25M 400%
common stock issued	4.98M -		100K -	3.45M 3,347%	11.74M 240.73%
common stock repurchased				-124K -
dividends paid				-3.45M -
other financing activites	-4 -		744K -	1.38M 85.62%	-2.05M 248.30%
net cash used provided by financing activities	6.09M -	-4K 100.07%	600K 15,100%	1.01M 67.83%	10.95M 987.09%
effect of forex changes on cash		106 -	3.84M 3,624,428.30%
net change in cash	3.21M -	-3.71M 215.70%	-247K 93.35%	-81K 67.21%	1.80M 2,320.99%
cash at beginning of period	612.65K -	3.82M 523.66%	337K 91.18%	90K 73.29%	9K 90%
cash at end of period	3.82M -	109K 97.15%	90K 17.43%	9K 90%	1.81M 19,988.89%
operating cash flow	-2.88M -	-3.71M 28.51%	-847K 77.15%	-1.08M 28.10%	-9.14M 742.40%
capital expenditure		-2K -		-3K -	-8K 166.67%
free cash flow	-2.88M -	-3.71M 28.58%	-847K 77.16%	-1.09M 28.45%	-9.15M 740.81%

COM:GRIBIO

GRI Bio, Inc.

Last Close

1.27

26/07 20:00

Market Cap

1.59M

Beta: -

Volume Today

457.28K

Avg: -

Preview